Skip to main content
Caplight Logo









HIROTSU BIO SCIENCE INC.

HIROTSU BIO SCIENCE INC.

Private
TokyoHealthcare & Life Scienceshttps://hbio.jp/

Last Round

Corporate Funding

Mar 31, 2025

Est. Valuation

$948.77M

Total Funding Raised

$18.03M

Company Overview

HIROTSU BIO SCIENCE INC. is a biotechnology company that developed N-NOSE, a cancer screening test that utilizes the olfactory sensory functions of nematodes to detect cancer from urine samples.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2C

Customer Profile

Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

cancer screeningnon-invasive cancer screeningearly cancer detectionmulti-cancer screeningliquid biopsynematode diagnosticsurine test for cancerat-home cancer testbiological diagnosticscancer screening kitmedical diagnosticsworm cancer testpancreatic cancer testAI-augmented diagnosticscorporate wellnessveterinary diagnosticscanine cancer screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HIROTSU BIO SCIENCE INC. Comparables

Compare HIROTSU BIO SCIENCE INC. with similar companies based on industry and business-model similarity.

HIROTSU BIO SCIENCE INC. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Craif Inc.
76%
Blue Industries
75%
GRAIL
72%

HIROTSU BIO SCIENCE INC. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingMar 31, 2025
Corporate FundingAug 2, 2024
Corporate FundingDec 1, 2023
Corporate FundingAug 23, 2022
Corporate FundingMar 11, 2022
Corporate Funding
Feb 16, 2021

Key People

Founding team and executive leadership

Takaaki Hirotsu

代表取締役, 代表取締役CEO

Executive Team

Eric di Luccio

CTO, Executive Director, Head Of R&D Department, Chief Technology Officer (CTO), Head Of R&D Center

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2025

    Completed a corporate funding round.

  • Aug 2, 2024

    Received funding from Eastern Car Liner, Ltd.

HIROTSU BIO SCIENCE INC. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HIROTSU BIO SCIENCE INC. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HIROTSU BIO SCIENCE INC.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range13
Year Founded2016
Last FundingMar 31, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?